You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Macromolecule Crystallization Screening Results Analysis

    SBC: iXpressGenes, Inc.            Topic: 100

    Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. microRNA-21 Blockade of Triple Negative Breast Cancer

    SBC: BOUND THERAPEUTICS LLC            Topic: 102

    Triple negative breast cancerTNBCis an orphan disease that attacksUS women every yearTNBC cells lack human estrogen receptorprogesterone receptorand epidermal growth factor receptorHerthe targets of existing medicinesTNBC recurs after standard of care chemotherapy and radiationkilling its victims withinyearsNew promising therapies such as poly ADP ribosepolymerasePARPinhibitors only benefit a smal ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Mid-IR LIDAR for Detecting Volatile Organic Compounds

    SBC: Princeton Technology Advisers Company Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): This project addresses the need for the development of field deployable, sensors which provide real-time quantitative measurements of Volatile Organic Compounds - airborne pollutants that are injurious to human health. In this particular case, benzene, formaldehyde and 1,3-butadiene. These three compounds have been identified as top cancer risk air pollutants T ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Mitochondrial Dysfunction in HAART: Point of Care Tests

    SBC: MITOSCIENCES, INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Mobile Phone Intervention for Physical Activity Maintenance in African American Men (MobileMen)

    SBC: KLEIN BUENDEL, INC.            Topic: NIMHD

    DESCRIPTION provided by applicant African American men experience health disparities across a number of preventable chronic diseases including cardiovascular disease strokes obesity and diabetes Physical activity PA is a modifiable risk factor for these conditions The few PA promotion studies that have included African American men have resulted in successful short term behavior change ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Modulation of the Innate Immune System by Fisetin for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government